Viking Therapeutics (VKTX) Misses Q4 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Viking Therapeutics Reports Fourth Quarter and Year-End 2015 Financial Results and Provides Corporate Update
March 8, 2016 4:05 PM ESTSAN DIEGO, March 8, 2016 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced financial results for the fourth quarter and year-end  2015, and provided an update on its clinical pipeline and other corporate developments.
Highlights from, and Subsequent to, the Year Ended December 31, 2015
"2015 was a successful and productive year for Viking," said Brian Lian, Ph.D., president and chief executive officer of Viking. "In the last twelve months, we completed... More
